



## Review

# Measurement of side effects of anti-epileptic drugs (AEDs) in adults with intellectual disability: A systematic review



Lauren Copeland<sup>b</sup>, Andrea Meek<sup>a,\*</sup>, Mike Kerr<sup>c</sup>, Michael Robling<sup>a</sup>, Kerry Hood<sup>a</sup>, Rachel McNamara<sup>a</sup>

<sup>a</sup> South East Wales Trials Unit, Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

<sup>b</sup> Division of Population Medicine, Cardiff University, Cardiff, United Kingdom

<sup>c</sup> Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, United Kingdom

## ARTICLE INFO

## Article history:

Received 16 March 2017

Received in revised form 13 July 2017

Accepted 19 July 2017

## Keywords:

Intellectual disability

Epilepsy

AED

Side-effect

PROM

## 1. Introduction

The prevalence of epilepsy in adults with an intellectual disability (ID) is up to 20 times greater than in the general population [1]. A recent survey of carers and professionals showed considerable concern over presence and impact of side effects from anti-epileptic drug (AED) treatment in people with ID (in particular drowsiness, memory problems, depression) [2]. The term *side effect* typically relates to any secondary undesirable effect of a treatment or drug. Physical, cognitive, behavioural or emotional side effects can cause significant impact on the quality of life of an individual. Monitoring side effects in adults with ID and epilepsy is challenging due to the commonly co-existing occurrence of behaviour and communication disorders [3]. The incidence of side effects is estimated to be as high as 58% in the wider population receiving treatment (i.e. adults with epilepsy without ID) [4]. Javed noted that patients with ID were less likely to report side effects than patients without ID, especially in regard to cognitive adverse events [5]. A recent Cochrane review concluded that side effects in the ID population are similar to the general

population, however the authors note that this is concluded from limited studies with unreliable measures [6].

The importance of Patient Reported Outcome Measures (PROMs) in assessing health status is increasingly acknowledged, both in research and in the evaluation of routine clinical care. In a report published in 2009 [7], the Medical Research Council (MRC) suggest several key areas for future research, including addressing gaps in currently available PROMs, such as for use at end of life and in children. However, the gap in available PROMs for use with adult ID populations and their families/carers would seem to be greater still. Screening tools are available to assess AED side effects in the general adult population, and research suggests that active monitoring is sufficient to change management and improve quality of life (QoL) [8]. It is not known however whether such tools can be used to identify side effects in adults with ID, or whether included items are important and relevant to patients and carers. The importance of developing PROMs that are reliable, valid and sensitive to change within the context of clinical trials has also been highlighted [9] and specification, selection and measurement of appropriate outcomes is central to all stages of the MRC guidance on complex intervention development [10]. However, a Cochrane review concluded that the measurement of side effects in this population was hampered by reliability of available measures [11]. In addition those with ID (and individuals with low literacy levels) are often excluded from the PROMs development process [9]. Therefore measures may not be accessible or acceptable to this population and are likely therefore to produce unreliable data if

\* Corresponding author at: South East Wales Trials Unit, Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, 4th Floor, Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, United Kingdom.

E-mail address: [meek@cardiff.ac.uk](mailto:meek@cardiff.ac.uk) (A. Meek).

poorly completed. This group is therefore at risk of exclusion from routine patient monitoring and quality improvement schemes thus increasing potential health inequalities [9].

The aim of this focused review is to identify literature on the measurement and impact of AED side effects in adult ID populations. Specifically, we wanted to determine whether side effects and their impact were being measured, and if so by what methods including whether self- or observer-reported and the nature of domains assessed. However, given that development of measures specific to this population has received little attention to date, we will also seek to identify measures of AED side effects in the wider adult epilepsy population that may be suitable for adaptation in ID populations. Results relating to identified side effect domains (e.g. adaptive functioning, cognitive symptoms) will be summarised according to population, medication type and AED/QoL measures where the data allow. This review forms part of a wider study which aims to develop a psychometrically sound measure of AED side effects that professionals can use in consultations with patients and carers to identify the important side effects of anti-epileptic drug (AED) treatment in adults with intellectual disability.

## 2. Methods

### 2.1. Study eligibility criteria

Selected studies met the following inclusion criteria:

- Adults with epilepsy (and an identified subset with ID).
- Participants were taking at least one AED as part of their treatment regime.
- Side effect outcome measure included.
- Qualitative or quantitative data.
- Articles published in English only.

Side effect outcome measures as stated in the methods section of the paper included, but were not limited to the following domains: seizure severity/frequency; psychiatric symptoms; social function; cognitive functioning; challenging behaviour; mood; quality of life; physical symptoms.

Studies were excluded if the seizure disorder occurred as a side effect of medical treatment or was not specified as epilepsy. Papers were excluded where no outcome data had been published. Papers reported from on-going studies which may be relevant (e.g. some feasibility/qualitative investigation of side effects which then informed outcome assessment) were included. For the full list of search terms see [Appendix A](#).

### 2.2. Information sources

Research articles were identified from MEDLINE In-Process, MEDLINE, EMBASE, SCOPUS and Web of Knowledge. We did not stipulate a date restriction. The search resulted in findings from: MEDLINE In-Process; 1946, MEDLINE; 1946, EMBASE; 1947, SCOPUS; 1945 and Web of Knowledge; 1950 all finishing in May 2015. We did not however search contact authors for any unpublished data.




Fig. 1. Diagram of review studies.

**Table 1**  
Summary of studies by side effect domain and measure.

Side Effect Domain	Measure	ID specific Yes/No	Rater according to study	Paper Reference
Adaptive functioning	Adaptive Behaviour Scale – Revised (ABS-R)	Yes	Carer	Kerr et al. [12]
Adverse Effects	Liverpool Adverse Events Profile (LAEP)	No	Self	Martins et al. [13], Zou et al. [14], Hakami et al. [15]
	Scale for the Evaluation and Identification of Seizures, Epilepsy, and Anticonvulsant Side Effects-B (SEIZES B)	Yes	Carer	
	Adverse Event Profile (AEP)	No	Self	Maschio et al. [17], Villagran et al. [18]
	WHO Toxicity Grading Scale for Determining the Severity of Adverse Events	No	Unclear	
Veterans Administration Cooperative study (Neurological and Systemic Adverse Event Rating Scales [N&SAERS])	No	Researcher	Chmielewska et al. [20], Chmielewska et al. [21]	
Anxiety	Zung Anxiety Scale (ZUNG-ANX)	No	Researcher	Ketter et al. [22]
	Hospital Anxiety and Depression Scale (HADS)	No	Self	Gillham et al. [23], Hardan et al. [24], Martins et al. [13], Mosaku et al. [25], Nabukenya et al. [26], Patariaia et al. [27], Smith et al. [28], Tang et al. [29], Tsounis et al. [30]
	Hamilton Anxiety Scale (HARS)	No	Self	Martinovic et al. [31], Mazza et al. [32], Mazza et al. [33], Tang et al. [29]
Beck Anxiety Inventory (BAI)	No	Self	Kim et al. [34]	
Behaviour	Matson Evaluation of Social Skills in Individuals with Severe Retardation (MESSIER)	Yes	Carer	Martin et al. [35]
	Aberrant Behavior Checklist (ABC)- Total	Yes	Carer	McKee et al. [36], McKee et al. [37], Martin et al. [35], Sunder et al. [38], Kerr et al. [12]
Behavioural adjustment	Minnesota Multiphasic Personality Inventory-2 (MMPI-2)	No	Unclear	Hessen et al. [39]
Behavioural disturbance	Whelan and Speake Rating Scale	Unclear	Unclear	Crawford et al. [40]
Challenging Behaviour	Key Carer-rated Visual Analogue Scales	Yes	Carer	Crawford et al. [40]
Cognitive	Mini Mental state examination (MME)	No	Self	Wu et al. [19]
	Dementia rating scale	No	Self	Martin et al. [41]
	Digit Span Forward	No	Researcher	Kalviainen et al. [42]
	Korean-California verbal learning test (K-CVLT)	No	Unclear	Kim et al. [34]
	Stroop Color- Word Interference	No	Self	Lee et al. [43], Xu et al. [44]
	EpiTrack	No	Unclear	Lutz et al. [45]
	Wechsler memory scale	No	Self	Martin et al. [41]
	Montreal Cognitive Assessment (MoCA)	No	Unclear	Nakhutina et al. [46]
	Corsi Block Span	No	Self	Kalviainen et al. [42]
	Korean-Boston naming test (K-BNT)	No	Unclear	Kim et al. [34]
	Controlled oral word association test	No	Self	Martin et al. [35]
	Alternating S Task	No	Researcher	Kalviainen et al. [42]
	A-B Neurotoxicity Scale.	No	Unclear	Nakhutina et al. [46]
	The A–B Neuropsychological Assessment Schedule	No	Unclear	Satischandra et al. [47]
	Rivermead Behavioural Memory Test (RBMT)	No	Researcher	Brandt et al. [48]
Cognitive/IQ	Wechsler Adult Intelligence Scale	No	Self	Kalviainen et al. [42], Kim et al. [34], Lee et al. [43], Lutz et al. [45], Sun et al. (2008) [49], Sunmonu et al. [50], Xu et al. [44], Brandt et al. [48]
Depression	Beck Depression Inventory (BDI)	No	Self	Fakhoury et al. [51], Rani et al. [52], Villagran et al. [18], Mazza et al. [32], Cho et al. [53], Martinovic et al. [31]
	Hamilton Depression Scale (HAM-D)	No	Self	Martinovic et al. [31], Mazza et al. [32], Mazza et al. [33]
	Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)	No	Self	
	Global assessment of severity of epilepsy (GASE) scale	No	Unclear	Wiebe et al. [57]
	Cornell Dysthymia Rating Scale-Self-Report (CDRS)	No	Self	Hardan et al. [58], Mazza et al. [32], Martinovic et al. [31]
	Patient Health Questionnaire (PHQ-9)	No	Unclear	Rathore et al. [54]
Center for Epidemiologic Studies Depression Scale (CES-D)	No	Self	Ettinger et al. [55], Mei [59]	
Geriatric Depression scale	No	Self	Martin et al. [41]	
Disability	Global Assessment of Epilepsy-Related Disability (GAERD)	No	Unclear	Sajobi et al. [60]
Functionality	Crichton Royal Behavioural Rating Scale	No	Unclear	Crawford et al. [40]
	Habilitative Improvement Scale	No	Carer	McKee et al. [36], McKee et al. [37], Sunder et al. [38]

Table 1 (Continued)

Side Effect Domain	Measure	ID specific Yes/No	Rater according to study	Paper Reference
Health	General Health Questionnaire (GHQ-28)	No	Self	Gillham et al. [61]
	Patient Health Questionnaire-9 (PHQ-9)	No	Self	Tesar et al. [62]
	Mental Health Inventory(MHI-5)	No	Unclear	Wagner et al. [63]
Quality of life	SEALS Side Effects and Life Satisfaction inventory	No	Self	Gillham et al. [4], Gillham et al. [23], Leach et al. [64]
	Profile of Mood States (POMS)	No	Self	Ettinger et al. [65], Fakhoury et al. [51], Gillham et al. [23] (Validation paper), Nakhutina et al. [46], Salinsky et al. [66], Smith et al. [67] (Outcomes paper), Smith et al. [28] (Seizure paper)
	Quality of Life Assessment Schedule (QOLAS)	No	Unclear	Kaiser et al. [68]
	Epilepsy Outcome Scale (EOS)	Yes	Researcher	Kerr et al. [12]
	Epilepsy and Learning Disabilities Quality of Life (ELDQoL)	Yes	Researcher	Kerr et al. [12]
	EORTC-QLQ-C30	No	Unclear	Maschio et al. [17]
	15D HRQoL instrument	No	Self	Stavem et al. [69]
	Medical Outcomes Study – Cognitive Functioning (MOS-COG)	No	Self	Gillham et al. [23] (Validation paper),
	Nottingham Health Profile (NHP)	No	Self	Smith et al. [67] (Outcomes paper), Smith et al. [28] (Seizure paper)
	TTO (Time Trade Off method)	No	Self	Stavem et al. [69]
	Visual Analogue Scale (VAS)	No	Unclear	Chmielewska et al. [20], Jozwiak et al. [70], Villagran et al. [18]
	Quality of Life in Epilepsy 89 (QOLIE-89)	No	Self	Engel et al. [71], Hakami et al. [15]
	Quality of Life in Epilepsy-Problems (QOLIE-31-P)	No	Self	De Backer et al. [72], Dunlap et al. [73], Anders et al. [74], Heo et al. [75]
	Quality of Life in Epilepsy (QOLIE-31)	No	Self	Marson et al. [76], Maschio et al. [17], Mosaku et al. [25], Nabukenya et al. [26], Fritz et al. [77], Heo et al. [78], Zou et al. [14]
	Quality of Life in Epilepsy (QOLIE-10)	No	Self	Satsichandra et al. [47], Semah et al. [79]
	Quality of Well-Being Self-Administered Scale (QWB-SA)	No	Self	Gao et al. [80]
	WHO Quality of Life-Brief version	No	Unclear	Shaw et al. [81]
	EuroQol instrument	No	Self	Stavem et al. [69], Selai et al. [82]
	Quality of Life Questionnaire (QOL-Q) Short-form 36	Yes	Self	Wang et al. [83]
		No	Unclear	Baker et al. [84], Smith et al. [67], Wagner et al. [63], Williams et al. [56]
	Quality of Life in Epilepsy 48 (QOLIE AD-48)	No	Self	Engel et al. [71]
	30-item General Health Questionnaire (GHQ-30)	No	Unclear	Mosaku et al. [25]
	Medical Outcomes Survey Short Form 12 (SF12)	No	Unclear	Semah et al. [79]
Social Problems Questionnaire	No	Self	Smith et al. [67]	
NEWQOL (Newly Diagnosed Epilepsy Quality of Life)	No	Self	Marson et al. [76]	
Modified Mini Mental State Examination (mMMSE)	No	Unclear	Mosaku et al. [25]	
Impact of Epilepsy (IoE) Scale	No	Self	Marson et al. [76], Satsichandra et al. [47]	
Impulsiveness	Barratt Impulsiveness Scale-11 (BIS-11)	No	Unclear	Helmstaedter et al. [85]
	Medication response	No	Self	Uijl et al. [86]
Mental and psychological health	Side Effect of Anti-Epileptic Drugs Ques. (SIDAED)	No	Self	
	Columbia-Classification Algorithm of Suicide Assessment (C-CASA)	No	Unclear	Biton et al. [87]
	Columbia-Suicide Severity Rating Scale (C-SSRS)	No	Self	Biton et al. [87], Rani et al. [52]
	Bunney-Hamburg Rating Scale	No	Researcher	Ketter et al. [22]
Mood	Beifindlichkeits-Skala (BFS)	No	Unclear	Fritz et al. [77]
	Cornell Dysthymia Rating Scale—Self-Report (CDRS)	No	Unclear	Hardan et al. [58], Mazza et al. [32], Ettinger et al. [65], Martinovic et al. [31]
	Profile of Mood States (POMS)	No	Unclear	Nakhutina et al. [46], Salinsky et al. [66], Ettinger et al. [65], Gillham et al. [23], Fakhoury et al. [51], Smith et al. [67]
	Amsterdamse Stemmingstest (ASL)	No	Self	Aldenkamp et al. [88]
	Montgomery and Asberg Depression Rating Scale (MADRS)	No	Researcher	Mazza et al. [33]
	Portland Neurotoxicity Scale (PNS)	No	Unclear	Salinsky et al. [66]
	Delighted-Terrible Scale	No	Self	Satsichandra et al. [47]
	Zung Self Rating Scale for Depression (Z-SDS)	No	Self	Mazza et al. [33]
Personality	Fragebogen zur Persönlichkeit bei zerebralen Erkrankungen (FPZ)	No	Unclear	Helmstaedter et al. [85]
Psychomotor performance	Digit-Symbol Substitution Test [DSST]	No	Unclear	Altman et al. [89]
Psychopathological function	Symptom Checklist 90—Revised (SCL-90-R) questionnaire	No	Self	Wu et al. [19]

**Table 1** (Continued)

Side Effect Domain	Measure	ID specific Yes/No	Rater according to study	Paper Reference
Sedation	Stanford Sleepiness scale	No	Unclear	Altman et al. [89], Salinsky et al. [90], Shah et al. [91]
	Epworth Sleepiness scale (ESS)	No	Unclear	Bonanni et al. [92], Cho et al. [53], Foldvary et al. [93], Shah et al. [91]
	Observer's Assessment of Alertness/Sedation Scale	No	Researcher	Altman et al. [89]
	Sedation score	No	Self	Gillham et al. [61]
Seizure severity	Clinical Global Impression of Change	No	Self	Anders et al. [74], Tsounis et al. [30]
	Liverpool Seizure Severity scale (LSSS)	No	Researcher	Baker et al. [84], Tesar et al. [62]
	National Hospital Seizure Severity Scale (NHS3)	No	Clinician	Cho et al. [53], Kaiser et al. [68], Peng et al. [94], Zou et al. [14]
	Seizure Severity Scale	No	Unclear	Smith et al. [67]
Sexual function	Changes in Sexual Function Questionnaire (CSFQ)	No	Self/Researcher	Gil-Nagel et al. [95]
	Arizona Sexual Experience scale (ASEX)	No	Unclear	Luef [96], Shah et al. [91]
	International index of Erectile Function-15	No	Unclear	Shaw et al. [81]
	Sexual Self efficacy scale for erectile functioning	No	Unclear	Shaw et al. [81]
Sleep	Medical Outcomes Study (MOS) Sleep Scale	No	Self	de Haas et al. [97]
	Pittsburg Sleep Quality Index (PSQI)	No	Unclear	Peng et al. [94], Cho et al. [53]
	Groningen Sleep Questionnaire (GSQ)	No	Self	de Haas et al. [97]
Symptom severity	25-item Seizure Severity Questionnaire (SSQ)	No	Self	Ettinger et al. [55]
	Global Evaluation Scale (GES)	No	Researcher	Heo et al. [75], Heo et al. [78]
Well Being	SEALS Side Effects and Life Satisfaction inventory	No	Self	Gillham et al. [4], Gillham et al. [23], Gillham et al. [98], Leach et al. [64], Marson et al. [76]

### 2.3. Search strategy

Appropriate keywords were used e.g: epilepsy, anti-epileptic drug, anticonvulsants, outcome measures/ment, scales, side effects, tolerability, seizure severity and frequency, psychiatric, cognition challenging behaviour, mood and quality of life (for details of the full search strategy see [Appendix A](#)). Each search term was classified under one of 4 categories: participants, medication, measures and side effect domains, which were combined (requiring all four domains to be included) in the database searches.

### 2.4. Data collection

Identified papers (n = 462) were assessed independently by two researchers and checked for eligibility of abstract and title according to the inclusion and exclusion criteria (see [Appendix A](#)). Studies that met inclusion criteria (n = 153) were obtained in full text and again checked for eligibility against the same criteria by one researcher. 40% were double checked independently for eligibility by a second researcher. Any disagreements identified were reviewed by both researchers and discussed to resolve differences. 95 eligible papers were included in the review.

### 2.5. Data extraction

A data extraction spreadsheet was created based on the research question. The data extraction fields included recruitment data, epilepsy and ID diagnosis, outcome measure and who completed the measure. The data extraction sheet was piloted and minor amendments made prior to being finalised.

### 2.6. Data synthesis

Each paper was summarised descriptively in terms of AED type, side effect domain, AED/QoL measures and who rated the measure (i.e. patient, carer/professional, proxy). Due to the nature of the

review aim, it was not possible to carry out a meta-analysis and a narrative synthesis was performed instead to summarize the outcome measures. Narrative synthesis is a systematic review and synthesis of multiple studies that is summarized in text format. The review had originally aimed to include a meta-analysis looking at associations between side effects and other important outcomes e.g. psychological well-being and challenging behaviour however no such data were reported.

## 3. Results

The initial search via electronic databases yielded 494 records and an additional 36 records were identified through hand searching. Subsequent removal of duplicates resulted in 462 papers remaining (see [Fig. 1](#)). Following independent review by two researchers of the abstracts according to the inclusion and exclusion criteria 153 studies were included for full paper review. From this selection 95 studies were identified as suitable for inclusion for the purposes of review.

### 3.1. Summary of studies by side effect domain and measure in general and ID adult epilepsy populations

[Table 1](#) presents a summary of studies by side effect domain and measure. The side effects measured by the studies range from adverse events, behavioural and cognitive changes, through to sexual functioning and quality of life. There are 108 measures used across all the studies. Eleven of these measures were used in the ID studies. Of the 108 measures, eight are designed for use with people with ID. The majority (51) of the measures for the general adult population were to be rated by the participant. This is in contrast to the measures used in the ID studies which were carer-rated.

### 3.2. Summary of studies with a focus on intellectual disability

Within the 95 papers identified as suitable for inclusion, the reviewers found eight studies that looked at adults with epilepsy

**Table 2**  
Summary of studies with a focus on ID.

Side effect domain	Paper	Participants (number, epilepsy diagnosis and ID diagnosis)	Type of AED	Measure	Results
Behavioural	Helmstaedter et al. [85]	<ul style="list-style-type: none"> <li>• 288 patients and 43 patients as a control group.</li> <li>• The type of epilepsy was not specified.</li> <li>• 14 participants were described as being 'mentally retarded' with 5% being in the LEV group and 14% in the control group</li> </ul>	288 patients on Levetiracetam (LEV) and 43 patients on other AEDs acting as a control group	<ul style="list-style-type: none"> <li>• Fragebogen zur Persönlichkeit bei zerebralen Erkrankungen</li> <li>• Barratt Impulsiveness Scale-11: BIS-11</li> </ul>	<ul style="list-style-type: none"> <li>• Negative side effects were reported more often in patients with ID than in general adult population patients.</li> <li>• Behavioral changes across the sample while taking LEV (12% very negative, 25% negative, 16% positive, and 6% very positive)</li> </ul>
	Martin et al. [35]	<ul style="list-style-type: none"> <li>• 21 patients age 4 years plus.</li> <li>• Any type of epilepsy or seizure.</li> <li>• A moderate to severe ID (ICD-10 classification: F71, 38%; F72, 52%).</li> </ul>	Topiramate	<ul style="list-style-type: none"> <li>• Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER).</li> <li>• Aberrant Behavior Checklist (ABC).</li> </ul>	<ul style="list-style-type: none"> <li>• The ABC and MESSIER tests indicated small improvements in the majority of behavioural aspects.</li> </ul>
	McKee et al. [36]	<ul style="list-style-type: none"> <li>• Patients aged at least 12 years of age.</li> <li>• Epilepsy with seizures classifiable by the International Classification of Seizures</li> <li>• An intellectual disability based on Diagnostic and Statistical Manual IV (DSM-IV) criteria. More than two-thirds were severely or profoundly 'mentally retarded'.</li> </ul>	Lamotrigine	<ul style="list-style-type: none"> <li>• Percentage of patients with reductions in seizure frequency.</li> <li>• Aberrant Behavior Checklist</li> <li>• Habilitative Improvement Scale. Adverse events</li> </ul>	<ul style="list-style-type: none"> <li>• Majority improvements in seizure frequency, duration and intensity.</li> <li>• No improvement or change in adverse events.</li> <li>• No change found relative to baseline for most patients with regards to intellectual and motor functioning.</li> <li>• Mean ABC scores for lethargy and stereotypy showed significant improvement,</li> <li>• Mean Habilitative Improvement Scale scores showed significant improvement.</li> <li>• Adverse events were reported in at least 5% of patients and included somnolence, dizziness, ataxia and emotional change.</li> </ul>
	McKee et al. [37]	<ul style="list-style-type: none"> <li>• Patients aged 12 to 20 years.</li> <li>• Refractory epilepsy.</li> <li>• An intellectual disability classifiable by the DSM-IV criteria. 64% had a classification of severe or profound 'mental retardation'.</li> </ul>	Lamotrigine	<ul style="list-style-type: none"> <li>• Aberrant Behaviour Checklist</li> <li>• Habilitative Improvement Scale</li> <li>• Adverse events and seizure counts were recorded by caregivers throughout the study.</li> </ul>	<ul style="list-style-type: none"> <li>• 60% of participants noted a 50% reduction in seizure frequency, 45% reported a 75% reduction, and 25% of participants reported zero seizures.</li> <li>• The mean score on the Habilitative Improvement Scale improved significantly from baseline.</li> <li>• Improvements in all 5 subdomain areas of the Aberrant Behavior Checklist.</li> <li>• 80% of participants did not experience any clinically relevant change in adverse effects.</li> <li>• Dizziness, somnolence, and abdominal pain were infrequently reported. Vomiting was the most common adverse event.</li> </ul>

**Table 2** (Continued)

Side effect domain	Paper	Participants (number, epilepsy diagnosis and ID diagnosis)	Type of AED	Measure	Results
	Sunder et al. [38]	<ul style="list-style-type: none"> <li>• 67 participants aged at least 12 years of age</li> <li>• A epilepsy diagnosis with seizures classifiable by the International Classification of Seizures.</li> <li>• Mild, moderate, severe or profound 'mental retardation' based on DSM IV criteria.</li> </ul>	Lamotrigine	<ul style="list-style-type: none"> <li>• Aberrant Behavior Checklist</li> <li>• Habilitative Improvement Scale.</li> <li>• Seizure counts by type of seizure were recorded by caregivers.</li> <li>• Adverse events recorded by caregivers.</li> </ul>	<ul style="list-style-type: none"> <li>• a reduction in seizure frequency, duration and intensity for most patients.</li> <li>• 81% of participants in institutional settings and 64% in community settings did not experience any change in adverse events.</li> <li>• The mean Habilitative Improvement Scale scores reflected improved functioning amongst the community based participants however the mean score was significantly improved in relation to the baseline phase for both groups of participants.</li> <li>• Lethargy, stereotypy, hyperactivity and inappropriate speech ABC domain scores were found to be significantly improved for the community based group.</li> <li>• No differences were found in any ABC domains for the group residing in institutional settings.</li> </ul>
Behavioural and functionality domains	Crawford et al. [40]	<ul style="list-style-type: none"> <li>• Participants aged 12 years and over</li> <li>• Participants were diagnosed with localisation-related epilepsy.</li> <li>• An intellectual disability and met the DSM-IV criteria for 'mental retardation' on a range of levels.</li> </ul>	Gabapentin and Lamotrigine	<ul style="list-style-type: none"> <li>• Key Carer-rated Visual Analogue Scales</li> <li>• Whelan and Speake Rating Scale</li> <li>• Crichton Royal Behavioural Rating Scale</li> <li>• Physician's Global Rating Scale.</li> </ul>	<ul style="list-style-type: none"> <li>• The results showed no difference between groups on the Visual Analogue Scales;</li> <li>• Both drugs seemed to reduce challenging behaviour as rated by Whelan and Speake Rating Scale.</li> <li>• Functionally improved significantly with gabapentin compared to lamotrigine as rated by the Crichton Royal Behavioural Rating Scale.</li> <li>• The Physician's Global Rating Scale showed statistically significant improvements over baseline (<math>P &lt; 0.01</math>) for challenging behaviour, seizure severity and general health for both treatment groups.</li> </ul>
Functionality and quality of life domain	Kerr et al. [12]	<ul style="list-style-type: none"> <li>• 74 participants aged 12 years and older.</li> <li>• A diagnosis of epilepsy</li> <li>• An intellectual disability defined as an IQ of &lt;70 (classified in accordance with the International Classification of Seizures).</li> </ul>	Topiramate	<ul style="list-style-type: none"> <li>• Adaptive Behaviour Scale</li> <li>• Aberrant Behaviour Checklist</li> <li>• Epilepsy Outcome Scale</li> <li>• Epilepsy and Learning Disabilities Quality of Life</li> </ul>	<ul style="list-style-type: none"> <li>• Adverse events reported were mainly those expected from people with epilepsy who were treated with Topiramate as add on therapy.</li> <li>• Placebo-treated patients reported nervousness as a side effect whereas patients on Topiramate reported somnolence.</li> <li>• No significant change in reported behaviour between the Topiramate and placebo groups.</li> <li>• The quality of life measures did not indicate any significant decline in quality of life.</li> </ul>
Cognitive domain	Brandt et al. [48]	26 participants	Topiramate	<ul style="list-style-type: none"> <li>• Rivermead Behavioural Memory Test</li> </ul>	<ul style="list-style-type: none"> <li>• All tests except digit span backward, naming test and RWT (letter B) showed significant differences on and off TPM, indicating an</li> </ul>

**Table 2** (Continued)

Side effect domain	Paper	Participants (number, epilepsy diagnosis and ID diagnosis)	Type of AED	Measure	Results
		<ul style="list-style-type: none"> <li>• A diagnosis of epilepsy and ID</li> <li>• An intellectual disability assessed according to ICD-10 criteria</li> </ul>		<ul style="list-style-type: none"> <li>• Digit Span Forward and backward task/Digital symbol test (HAWIE-R)</li> <li>• Regensburger Wortflussigkeitstest (RWT)</li> <li>• Trail Making Test (D-KEFS)</li> </ul>	<p>impairment of cognitive functioning by TPM in patients with ID</p> <ul style="list-style-type: none"> <li>• Attention, speed, verbal short term memory and verbal fluency were affected</li> </ul>

and ID, who were taking an AED and measured side effects using an outcome measure. These studies have been grouped by side effect domain and AED type. Five of the studies [35,37,38,85] examined only behavioural domains. One paper [40] looked at behaviour as well as functionality and one paper examined cognitive adverse events [48]. The final paper [12] examined both functionality and quality of life. Table 2 summarizes studies identified which have a focus on intellectual disability.

All of the above studies investigate the effectiveness of specific AED drugs on participants with epilepsy and ID. The studies report the efficacy of the AED and any side effects. Several AEDs are examined and there are a mixture of results in terms of efficacy and side effects. Some of the studies report improvements within side effect domains [16–18,20], whilst other studies showed no or little improvement [35,82,85].

The studies use the various measures to investigate behaviour, functionality, cognitive and quality of life domains, however, studies also recorded adverse events. One study [35] reported 57 treatment-emergent adverse events (TEAEs) in 21 of the 29 patients from a safety cohort (72.4%) during treatment. Gastrointestinal disorders and nervousness/restlessness (4 of 29 safety set patients) and tiredness/sedation/adynamia, ear/nose/throat infections, injuries, and mental state disorders (3 patients each) were the adverse effects captured most frequently [35]. Further studies [12,36–38], also reported adverse events deemed to be drug-related including somnolence, dizziness, ataxia, emotional change and vomiting. Therefore although there are a number of measures which focus on side effects it is also noted that adverse event recording is an alternative way of capturing information about side effects as opposed to using specific outcome measures.

Helmstaedter et al. [85] suggest that patients with ID reported negative side effects more often than patients with normal development. This highlights the need for a measure of AED side effects for those with ID. According to the authors of the other studies [35–38] identified in this review, ABC, MESSIER and Habilitative Improvement Scale scores are sensitive to change. Crawford et al. [40] stated that although they found no difference between the groups in their study for challenging behaviour, functioning did improve significantly with Gabapentin compared to Lamotrigine. Both groups showed statistically significant improvements over baseline ( $P < 0.01$ ) for challenging behaviour, seizure severity and general health. The same study also found no significant change in reported behaviour between the Topiramate and placebo groups, using a specific behaviour change measure. Concurrently the quality of life measures did not indicate any significant decline in quality of life. From these results there appear to be no significant side effects from the intervention AEDs, although this may reflect the choice of measure or proxy-assessment, rather than the absence of any negative effects.

Side effects and adverse events were assessed within each study using variable methods. For example Crawford et al. [40]

recorded seizure occurrences in diaries and safety and tolerability were assessed by adverse event reports, however it is not noted who completed these diaries or reports (i.e. if they were completed by the participant or the carer). Minimal details regarding method of recording adverse events and seizure occurrence are included within the method sections of these papers. For example, Sunder et al. [38] notes that adverse events and seizure occurrence were recorded by caregivers however no further details are available on the formats used to collect this data. There were no studies which included self-reported measures of seizure occurrence or adverse/side effects.

The functionality domain measures included in this review were the Adaptive Behaviour Scale (ABS-R) [99], the Habilitative Improvement Scale [100] and the Crichton Royal Behavioural Rating Scale [101]. The ABS-R and Habilitative Improvement Scale were again carer rated, in the studies reported. The Habilitative Improvement Scale and Crichton Royal Behavioural Rating Scale are recommended for carer-completion, possibly to provide a more objective assessment of functionality. With the exception of the Adaptive Behaviour Scale these measures have not been developed to measure functionality in patients with ID.

The final side effect domains noted in these studies were quality of life and cognitive adverse events. In relation to cognitive changes Brandt [48] strongly recommended that these adverse events are assessed during the course of treatment, and that the effective assessment of adverse events in people with epilepsy is essential as the occurrence of such events has an impact on a persons' quality of life, in patients who are able to follow the instructions established neuropsychological instruments may be used. Quality of Life was measured using the Epilepsy and Learning Disabilities Quality of Life (ELDQoL) [102] measure and the Epilepsy Outcome Scale [103]. Both of these measures were developed specifically for people with ID to be rated by their carer. Although it is positive these measures were developed for the ID population they do not gather the data from the ID patient themselves leading to proxy quality of life scores.

#### 4. Measures of side effects

Table 3 outlines side effect measures identified within included studies. The outcome measures identified with a focus on behaviour as a side effect domain included Key Carer-rated Visual Analogue Scales [20], Matson Evaluation of Social Skills in Individuals with Severe Retardation (MESSIER) [104], Aberrant Behavior Checklist (ABC) [105], Barratt Impulsiveness Scale-11 (BIS-11) [106], Fragebogens zur Persönlichkeit bei zerebralen Erkrankungen (FPZ) and the Whelan and Speake Rating Scale [107]. All these measures apart from the Key Carer-rated Visual Analogue Scale and the Barratt Impulsiveness Scale-11 (BIS-11), were carer-rated in the reported studies. The BIS-11, FPZ and Whelan and Speake Rating Scale were not developed for use in ID populations

**Table 3**  
Measures of side effect identified within included studies.

Measure	Focus of Measure	Target responder according to study	Target responder according to measure	ID specific (Yes/No)	Study Reference
Key Carer-rated Visual Analogue Scales [40]	Challenging behaviour	Carer	Carer	Yes <sup>a</sup>	Crawford et al. [40]
Fragebogens zur Persönlichkeit bei zerebralen Erkrankungen (FPZ) [108]	Personality	Carer/self	Self	No	Helmstaedter et al. [85]
Adaptive Behaviour Scale- Revised (ABS-R) [99]	Adaptive behaviour/ functioning	Carer	Carer	Yes	Kerr et al. [12]
Matson Evaluation of Social Skills in Individuals with Severe Retardation (MESSIER) [104]	Behaviour	Carer	Carer	Yes	Martin et al. [35]
Aberrant Behavior Checklist (ABC) [105]	Behaviour	Carer	Carer	Yes	Kerr et al. [12], Martin et al. [35], McKee et al. [36], McKee et al. [37], Sunder et al. [38]
Habilitative Improvement Scale [100]	Adaptive behaviour/ functioning	Carer	Carer	No	McKee et al. [36], McKee et al. [37], Sunder et al. [38]
Barratt Impulsiveness Scale-11 (BIS-11) [106]	Impulsive-ness	Carer/self	Self	No	Helmstaedter et al. [85]
Epilepsy Outcome Scale (EOS) [103]	Concerns about epilepsy	Carer	Carer	Yes	Kerr et al. [12]
Crichton Royal Behavioural Rating Scale [101]	Adaptive behaviour/ functioning	Carer	Carer	No	Crawford et al. [40]
Epilepsy and Learning Disabilities Quality of Life (ELDQoL) [102]	Health related QoL	Carer	Carer	Yes	Kerr et al. [12]
Whelan and Speake Rating Scale [107]	Behavioural disturbance	Carer	Not known <sup>b</sup>	Not known <sup>b</sup>	Crawford et al. [40]

<sup>a</sup> Scale developed specifically for study.

<sup>b</sup> Out of print.

and therefore may not take account of the potential differences in behavioural side effects experienced in ID and general adult and elderly epilepsy populations [6].

## 5. Discussion

We chose to undertake a review of the measurement and impact of AED side effects in general and adult intellectual disability populations, with a particular focus on results relating to identifying side effect measures of AED use (e.g. adaptive functioning, cognitive symptoms) either specifically designed for use in ID populations, or that could be adapted for this purpose. We identified 95 eligible papers, eight of which [12,35–38,40,48,82], focused specifically on ID populations. The side effects measured by the studies range from adverse events, behavioural and cognitive, through to sexual function and quality of life. The majority of the measures for the general adult population were to be rated by the participant. This is in contrast to the measures used in the ID studies which were carer-rated. These findings replicate those of Townsend et al. who undertook a systematic review of quality of life measures for people with intellectual disabilities and challenging behaviours, reporting that the number of subjective (self-reported) quality of life measures appropriate for use by people with intellectual disabilities is limited [109]. Outcome measures identified in this review can be broadly categorised within the following side effect domains; behaviour, impulsiveness, functionality, cognitive and quality of life.

The measures identified in this review do not typically contain sufficient and appropriate content to identify changes in the overall side effects of AED's in ID populations. They are generally by-proxy measures of behavior or mood change, and as such lack face and content validity in the context of drug effects. Reliability and validity of the identified measures are not therefore reported in this paper.

The term *side effect* is defined as: “Any unwanted nontherapeutic effect caused by a drug” [110]. *Adverse events* are defined in

Article 2(m) of Directive 2001/20/EC as: “Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment” [111].

In the papers identified in this review, the terms “side effect” and “adverse events” are used interchangeably throughout. Such side effects or adverse events are seldom focused on in the same way and cover a wide range of impacts, for example on adaptive or challenging behaviour or quality of life. Side effects and adverse events are generally measured in an ad hoc manner, with no standardised way of recording type or frequency of occurrence. In the majority of cases, events are carer-reported or the responder is unspecified. Given the methodology otherwise reported, particularly if diaries or standardised measures are used, it is likely that assessments are made by carers if not otherwise specified.

Studies have also included adverse events reported by participants to the clinician or researcher. Furthermore, these adverse events are not explicitly addressed by the outcome measures used by the included studies within this review. As the treatment-emergent adverse events referred to above were reported voluntarily by participants, these may represent side effects that they were particularly concerned about, were severe or that occurred most frequently.

Thompson [2] undertook a qualitative study of carer and professional views on the management of people with intellectual disability and epilepsy and found that respondents noted a number of side effects, but that the impact of these side effects was not well understood by clinicians, who in some cases demonstrated a lack of empathy with patients and families. One family member noted that including the patient in discussions helps:

*“I sometimes feel that a percentage of people taking AEDs would be, on the whole, better off without them. Side-effects are often passed off as being unimportant and the recommendation generally is to continue increasing a drug. Listening to the patient helps” [2].*

Kerr states that it is important to recognise that the majority of patients in this population are unable to self-report side effects and

as such there is a tendency for only the more overt side effects (such as vomiting or weight gain) to come to the attention of the clinician [3]. Our findings suggest that side effects of AEDs are inconsistently and inadequately measured in ID populations, and as such are likely to be under-reported. This is consistent with a broader debate reported in the literature focusing on the absence of the patients' voice in drug trials. The adverse events that are reported during drugs trials are almost entirely clinicians' impressions of patients symptoms rather than the patients report [112]. Further to this issue a recent review [113] has found the clinician reporting of adverse events provides complementary information to patient reported outcome measures. Integration of these two measures could improve clinicians and policy makers interpretations of clinical trials. It is not known whether currently available PROMs used in the general adult population can be used to identify side effects in adults with ID, or whether the items included in existing measures are important and relevant to this group of patients and their carers. Furthermore, one of the two outcome measures identified that is designed for an ID population, is intended to be rated by carers, and focuses on the more theoretical concept of quality of life (which in practice may be poorly defined) rather than on side effects of medication per se.

The results of the current review would seem to support the assertion that patients themselves may not be as involved in discussion as they should be, and that outcome measures developed specifically for use in adults with epilepsy and ID are either not available or not commonly used. Furthermore, clinicians and researchers alike appear to have a preference for using proxy rather than patient assessment. However, this may be due to availability of suitable measures.

There are several limitations within this review. In one study [85] only 14 out of 331 participants were reported to have had an intellectual disability. However this was taken from patient files and not from psychometric evaluations, so the real figure may have been different. Due to these low numbers the study may have used different measures more appropriate for the general population rather than the ID population. A further limitation of the review is that the grey literature was not searched.

The low numbers of studies identified relating specifically to the ID population shows there is a clear need for further research in this field. It should also be noted that although the majority of measures were not developed specifically for the ID patient population they may nevertheless be useful instruments within the clinical setting. Measures are frequently used for research/evaluation purposes and so further investigation would be helpful in identifying why such measures are not utilized in the clinical environment.

## 6. Conclusion

Measurement tools are available to assess AED side effects in the general adult population, however as demonstrated by this review there are limited outcome measures designed specifically to be used in ID populations. Furthermore, the focus of these measures is broader than side effects alone, and as such they may not be sufficiently in-depth to pick up the full range of side effects of importance in this group.

Research suggests that active monitoring of AED side effects in the general adult population is sufficient to change management and improve quality of life (QoL) [8]. Therefore, there is a need for measures developed specifically to address the potentially different impact of these medications in patients with ID. Given the high level of comorbidities such as Autistic Spectrum Disorder or mental health issues and concomitant medication use these are factors which also need to be considered within the ID population when examining the side effects of AED medication. Within this

study there were no measures identified which focused on populations of people with Autism. With regards to AED side effects in the ID population Kerr (2009) recommended within international consensus guidelines, that baseline cognitive and behavioural assessments should be made and then re-measured after drug changes, with validated measures preferred [3]. There is a lack of established and validated assessment scales for patients with ID and epilepsy, but the fact that this is a heterogenous population and there is a wide range of diversity in communication and cognitive deficits, mean it is challenging to develop a scale or measure that is suitable for all. Thornicroft and Tansella [114] suggest that important properties for patient based outcome measures are feasibility, appropriateness, reliability, validity, responsiveness, precision, interpretability and, acceptability. In ID populations, several additional factors should also be considered in order for the measure to be truly patient reported such as adaptability for capacity, accessibility and length/completion time, to facilitate use in a busy clinical setting. Nevertheless there is a clear need to develop a psychometrically sound measure that allows patients with epilepsy and ID to self-report the side effects of their AED medication as far as is possible.

## Disclosure of conflicts of interest

None of the authors has any conflict of interest to disclose.

## Ethical publication statement

We confirm that we have read the Journals' position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

## Acknowledgments

The current study was funded by Epilepsy Research UK. (Grant number: P1404)

## Appendix A. Search strategy evidence synthesis SIDE-PRO

### Research Question

What is the measurement and impact of Anti-Epileptic Drug (AED) side effects in general and adult ID populations?

### PICO

Participants: general adult population with epilepsy.

Intervention: A measure or scale to measure AED side effects.

Comparison: No comparison.

Measurement: outcome measures/scales of AED side effects, patient reported outcome measures.

Outcomes: Side effects of AEDs, adverse effects, quality of life, cognitive function and challenging behaviour.

### Methods

A search strategy was developed for electronic databases on Ovid Medline using both keywords and MeSH headings. The developed search strategy is below. The named anti-epileptic drugs were chosen in consultation with medical professionals. The search strategy was modified to search the rest of the databases.

Bibliographic Databases	Number of results
EMBASE	96
MEDLINE	295
MEDLINE IN PROCESS	23
SCOPUS	8
WEB OF KNOWLEDGE	5

---

MESH and keywords  
 Participants  
 Epilepsy  
 Drugs  
 Anti Epileptic Drug  
 Anti epilep\$  
 AED  
 Anticonvulsants  
 Felbamate  
 Gabapentin  
 Lamotrigine  
 Levetiracetam  
 Oxcarbazepine  
 Topiramate  
 Vigabatrin  
 Zonisamide

Measures  
 Outcome measures/ment  
 Scales  
 Patient reported outcome measures

Outcomes  
 Side effects  
 Adverse effects  
 Tolerability  
 Seizure severity and frequency  
 Seizure  
 Psychiatric  
 Social functioning  
 Cognitive function  
 Cognitive side effect  
 Cognition  
 Memory  
 Challenging behaviour  
 Behaviour/al  
 Behaviour problems  
 Mood  
 Quality of life

---

To be eligible, studies would need to include:

Adults AND epilepsy (but we want to identify sub-set with LD/  
 ID) AND medication AND side effects AND scale/outcome measure.

## References

- [1] Emerson E, Glover G. Health checks for people with learning disabilities: 2008/9 & 2009/10. *Improving health & lives: Learning disabilities observatory*. .
- [2] Thompson R, Linehan C, Glynn M, Kerr M. A qualitative study of carers' and professionals' views on the management of people with intellectual disability and epilepsy: a neglected population. *Epilepsy Behav* 2013;28:379–85.
- [3] Kerr M, Scheepers M, Arvio M, Baevis J, Brandt C, Brown S, et al. Consensus guidelines into the management of epilepsy in adults with an intellectual disability. *Intellect Disabil Res* 2009;53(8):687–94.
- [4] Gillham R, Baker G, Thompson P, Birbeck K, McGuire A, Tomlinson L, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. *Epilepsy Res* 1996;24:47–55.
- [5] Javed A, Cohen B, Detyniecki K, Hirsch LJ, Legge A, Chen B, et al. Rates and predictors of patient reported cognitive side effects of anti-epileptic drugs: an extended follow up. *Seizure* 2015;29:34–40.
- [6] Jackson CF, Makin SM, Marson AG, Kerr M. Pharmacological interventions for epilepsy in people with intellectual disabilities. *Cochrane Database Syst Rev* 2015(9) Art. No.: CD005399.
- [7] Medical research council patient-reported outcome measures (PROMs): Identifying UK research priorities. London: Medical Research Council; 2009.
- [8] Gilliam F, Fessler A, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects A randomized trial. *Neurology* 2004;62:23–7.
- [9] Jahagirdar D, Kroll T, Ritchie K, Wyke S. Using patient reported outcome measures in health services: a qualitative study on including people with low literacy skills and learning disabilities. *BMC Health Serv Res* 2012;12:431.
- [10] Medical research council developing and evaluating complex interventions: new guidance. London: MRC; 2008.
- [11] Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities. *Cochrane Database Syst Rev* 2007(3) Art. No.: CD005399. Epub 2007 Jul 18.
- [12] Kerr MP, Baker GA, Brodie MJ. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. *Epilepsy Behav* 2005;7:472–80.
- [13] Martins HH, Alonso NB, Vidal-Dourado M, Carbonel TD, de Araujo Filho GM, Caboclo LO, et al. Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese-Brazilian validation of the Liverpool adverse events profile. *Epilepsy Behav* 2011;22:511–7.
- [14] Zou X, Hong Z, Chen J, Zhou D, Zou X, Hong Z, et al. Is antiepileptic drug withdrawal status related to quality of life in seizure-free adult patients with epilepsy? *Epilepsy Behav* 2014;31:129–35.
- [15] Hakami T, Todaro M, Petrovski S, Macgregor L, Velakoulis D, Tan M, et al. Substitution monotherapy with levetiracetam vs older antiepileptic drugs: a randomized comparative trial. *Arch Neurol* 2012;69:1563–71.
- [16] Matson JL, Laud RB, Gonzalez ML, Malone CJ, Swender SL. The reliability of the scale for the evaluation and identification of seizures, epilepsy, and anticonvulsant side effects-B (SEIZES B). *Res Dev Disabil* 2005;26:593–9.
- [17] Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. *J Neuro-Oncol* 2012;106:651–6 [Erratum appears in *J Neurooncol*. 2012 Feb;106:657–9].
- [18] Villagran A, Mevag MA, Kjaervik V, Johannessen S, Landmark CJ, Henning O. Adherence concerning antiepileptic medication: the patients' view. *Epilepsy Curr* 2015;15:340.
- [19] Wu T, Chen CC, Chen TC, Tseng YF, Chiang CB, Hung CC, et al. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study. *Epilepsy Behav* 2009;16:468–74.
- [20] Chmielewska B, Stelmasiak Z. Clinical evaluation of gabitril and lamictal for drug-resistant epilepsy in adults. *Ann Univ Mariae Curie Sklodowska Med* 2001;56:35–42.
- [21] Chmielewska B, Lis K, Rejdak K, Balcerzak M, Steinborn B. Pattern of adverse events of antiepileptic drugs: results of the aESCAPE study in Poland. *Arch Med Sci* 2013;9:858–64.
- [22] Ketter TA, Malow BA, Flamini R, Ko D, White SR, Post RM, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. *Epilepsy Res* 1996;23:129–37.
- [23] Gillham R, Bryant-Comstock L, Kane K, Brodie MJ. Validation of the side effect and life satisfaction (SEALS) inventory. *Seizure* 2000;9:458–63.
- [24] Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2004;14:426–32.
- [25] Mosaku KS, Fatoye FO, Komolafe M, Lawal M, Ola BA. Quality of life and associated factors among adults with epilepsy in Nigeria. *Int J Psychiatry Med* 2006;36:469–81.
- [26] Nabukenya AM, Matovu JK, Wabwire-Mangen F, Wanyenze RK, Makumbi F. Health-related quality of life in epilepsy patients receiving anti-epileptic drugs at National Referral Hospitals in Uganda: a cross-sectional study. *Health Qual Life Outcomes* 2014;12:49.
- [27] Pataria E, Jung R, Bonelli-Nauer S, Trimmel K, Aull-Watschinger S. Prescription patterns and self-reported side effects of antiepileptic drugs in patients with epilepsy at tertiary referral center in Austria. *Epilepsy Curr* 2013;13:433.
- [28] Smith D, Chadwick D, Baker G, Davies G, Dewey M. Seizure severity and the quality of life. *Epilepsia* 1993;34(Suppl. 5):S31–5 Abstract.
- [29] Tang WK, Lu J, Ungvari GS, Wong KS, Kwan P. Anxiety symptoms in patients with frontal lobe epilepsy versus generalized epilepsy. *Seizure* 2012;21:457–60.
- [30] Tsounis S, Kimiskidis VK, Kazis D, Gkias K, Garganis K, Karageorgiou K, et al. An open-label, add-on study of pregabalin in patients with partial seizures: a multicenter trial in Greece. *Seizure* 2011;20:701–5.
- [31] Martinovic Z, Buder N, Milovanovic M, Velickovic R. Antiepileptic, behavioral, and antidepressant effects of adjunct lamotrigine therapy in drug-resistant epilepsy. *Vojnosanit Pregl* 2004;61:485–90.
- [32] Mazza M, Della Marca G, Di Nicola M, Martiniotti G, Pozzi G, Janiri L, et al. Oxcarbazepine improves mood in patients with epilepsy. *Epilepsy Behav* 2007;10:397–401.
- [33] Mazza M, Martini A, Scopetta M, Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:539–43.
- [34] Kim D, Han SW, Joo EY, Yoon SM, Choi SJ, Hong SB. Effect of oxcarbazepine monotherapy on cognition and bone mineral density in adults with epilepsy. *Epilepsy Curr* 2012(12)(Suppl. 1) 1.258. Abstract.
- [35] Martin P, Schreiner A, Rettig K, Schauble B. Topiramate in patients with epilepsy and intellectual disability. *Epilepsy Behav* 2009;14:496–502.
- [36] McKee J, Sunder T, FineSmith R, Vuong A, Varner JA, Hammer AE, et al. Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. *Epilepsy Behav* 2003;4:386–94.

- [37] McKee JR, Sunder TR, Vuong A, Hammer AE. Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. *J Child Neurol* 2006;21:372–9.
- [38] Sunder TR, McKee JR, Hammer AE, Vuong A. Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. *Curr Med Res Opin* 2006;22:693–702.
- [39] Hessen E, Lossius MI, Gjerstad L. Behavioural adjustment in seizure-free epilepsy patients on monotherapy. *Seizure* 2008;17:422–30.
- [40] Crawford P, Brown S, Kerr M. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. *Seizure* 2001;10:107–15.
- [41] Martin RC, Griffith HR, Faught E, Gillam F, Mackey M, Vogtle L. Cognitive functioning in community dwelling older adults with chronic partial epilepsy. *Epilepsia* 2005;46:298–303.
- [42] Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Reikkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. *Arch Neurol* 1995;52:989–96.
- [43] Lee SA, Lee HW, Heo K, Shin DJ, Song HK, Kim OK, et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. *Seizure* 2011;20:49–54.
- [44] Xu F, Feng QH, Yu L, Liu J, Sun HB. Effects of topiramate versus other antiepileptic drugs on the cognitive function of patients with epilepsy. *Neural Regen Res* 2007;2:95–8.
- [45] Lutz MT, Helmstaedter C. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. *Epilepsy Behav* 2005;7:708–14.
- [46] Nakhutina L, Kunnakkat SD, Coleman M, Lushbough C, Arnedo V, Soni N, et al. Effects of adjunctive lacosamide on mood and quality of life in adult patients with localization related epilepsy. *Epilepsy Curr* 2015;15:38–9.
- [47] Satischandra P, Rao SL, Ravat S, Jayalakhsmi S, Senapathy A, Shah U, et al. The effect of phenobarbitone on cognition in adult patients with new onset epilepsy: a multi-centric prospective study from India. *Epilepsy Res* 2014;108:928–36.
- [48] Brandt C, Lahr D, May T. Cognitive adverse events of topiramate in patients with epilepsy and intellectual disability. *Epilepsy Behav* 2015;45:261–4.
- [49] Sun W, Wang Y, Wang W, Wu X. Attention changes in epilepsy patients following 3-month topiramate or valproate treatment revealed by event-related potential. *Int J Psychophysiol* 2008;68:235–41.
- [50] Sunmonu TA, Komolafe MA, Ogunrin AO, Oladimeji BY, Ogunniyi A. Intellectual impairment in patients with epilepsy in Ile-Ife, Nigeria. *Acta Neurol Scand* 2008;118(6):395–401.
- [51] Fakhoury TA, Miller JM, Hammer AE, Vuong A. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. *Drugs Aging* 2008;25:955–62.
- [52] Rani RA, Razali R, Hod R, Mohamad K, Rani S, Yahya W, et al. Suicidal ideation amongst epilepsy patients in a tertiary centre. *Neurol Asia* 2014;19:129–36.
- [53] Cho YW, Kim DH, Motamedi GK. The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. *Seizure* 2011;20:336–9.
- [54] Rathore JS, Tesar GE, Obuchowski N, Busch R, Humbel D, Jehi LE. Correlations of PHQ-9 with NDDI-E in epilepsy patients: a pilot study. *Epilepsy Curr* 2013;13:258.
- [55] Ettinger AB, Good MB, Manjunath R, Edward FR, Bancroft T. The relationship of depression to antiepileptic drug adherence and quality of life in epilepsy. *Epilepsy Behav* 2014;36:138–43.
- [56] Williams HE, Bagary M. Anxiety and quality of life in patients with epilepsy and psychogenic non-epileptic seizures. *Epilepsy Curr* 2010(11)(Suppl. 1) 3.288.Abstract.
- [57] Wiebe S, Sajobi T, Jette N, Patten S, Engbers J, Fiest K, et al. Construct validity of global assessment severity of epilepsy (gase) scale in adult epilepsy patient population. *Epilepsy Curr* 2014;14:128–9.
- [58] Harden CL, Lazar LM, Pick LH, Nikolov B, Goldstein MA, Carson D, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. *Epilepsia* 1999;40:1129–34.
- [59] Mei PA, Montenegro MA, Guerreiro MM, Guerreiro CA, Mei PA, Montenegro MA, et al. Pharmacovigilance in epileptic patients using antiepileptic drugs. *Arq Neuropsiquiatr* 2006;64:198–201.
- [60] Sajobi T, Jette N, Wiebe S, Patten S, Engbers J, Fiest K, et al. Global assessment of epilepsy-related disability scale: a new measure of disability in patients with epilepsy. *Epilepsy Curr* 2014;14:126–7.
- [61] Gillham RA, Blacklaw J, McKee PJ, Brodie MJ. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. *J Neurol Neurosurg Psychiatry* 1993;56:1271–5.
- [62] Tesar GE, Jehi L, Najm I. Prevalence and predictors of depression in 2,128 epilepsy patients. *Epilepsy Curr* 2010(11)(Suppl. 1) 3.252.Abstract.
- [63] Wagner AK, Keller SD, Kosinski M, Baker GA, Jacoby A, Hsu MA, et al. Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy on patients' health-related quality of life. *Qual Life Res* 1995;4:115–34.
- [64] Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. *J Neurol Neurosurg Psychiatry* 1997;62:372–6.
- [65] Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. *Epilepsy Behav* 2007;10:148–54.
- [66] Salinsky MC, Storzbach D. The Portland neurotoxicity scale: validation of a brief self-report measure of antiepileptic-drug-related neurotoxicity. *Assessment* 2005;12:107–17.
- [67] Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. *Epilepsia* 1993;34:312–22.
- [68] Kaiser S, Selai CE, Trimble MR. Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life. *Seizure* 2002;11:356–60.
- [69] Stavem K. Quality of life in epilepsy: comparison of four preference measures. *Epilepsy Res* 1998;29:201–9.
- [70] Jozwiak S, Terczynski A. Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. *Seizure* 2000;9:486–92.
- [71] Engel Jr J, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. *J Am Med Assoc* 2012;307:922–30.
- [72] De Backer M, Borghs S, Hebert D, Sake JK, Cramer J. Lacosamide added to concomitant AEDs grouped by mechanism of action-impact on patient-reported health-related quality of life in pooled phase II/III trials. *Epilepsy Curr* 2012(12)(Suppl. 1) 2.246.Abstract.
- [73] Dunlap SD, Lervik K, Bainbridge J, Strom L. Objective self-measurement of the subjective side effect of dizziness on sodium channel blocking AEDs. *Epilepsy Curr* 2014;14:222.
- [74] Anders B, Hogan RE, Chung SS, Clark AM, Blatt I. Clinical and quality of life assessments following long-term treatment with USL255 (qudexy<sup>TM</sup> XR; extended-release topiramate) in patients with refractory partial-onset seizures: prevail ole. *Epilepsy Curr* 2015;15:317–8.
- [75] Heo K, Lee BI, Yi SD, Huh K, Kim JM, Lee SA, et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. *Seizure* 2007;16:402–9.
- [76] Marson AG, Appleton R, Baker GA, Chadwick D, Doughty J, Eaton B, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. *Health Technol Assess* 2007;11:1–134.
- [77] Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. *Epilepsy Behav* 2005;6:373–81.
- [78] Heo K, Lee BI, Yi SD, Cho YW, Shin DJ, Song HK, et al. Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. *Seizure* 2012;21:188–93.
- [79] Semah F, Thomas P, Coulbaut S, Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. *Epileptic Disord* 2014;16:165–74.
- [80] Gao L, Xia L, Pan S-Q, Xiong T, Li S-C. Validation of a Chinese version of the Quality of well-being scale-self-administered (QWB-SA) in patients with epilepsy. *Epilepsia* 2013;54:1647–57.
- [81] Shaw D, Patnaik P, Rathee VS, Khan S, Trivedi S, Dwivedi US. Sexual dysfunction in indian epileptic male population—a prospective study. *Indian J Urol* 2015;31:S109.
- [82] Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. *Seizure* 1999;8:8–13.
- [83] Wang TG, Wang H, Cheng JH. Eleven influential factors for quality of life in adults with epilepsy. *Neural Regen Res* 2008;3:422–6.
- [84] Baker GA, Currie N, Light M, Schneiderman J. The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy – a Canadian study. *Seizure* 2002;11:6–15.
- [85] Helmstaedter C, Fritz N, Kockelmann E, Kosanetzky N, Elger CE. Positive and negative psychotropic effects of levetiracetam. *Epilepsy Behav* 2008;13:535–41.
- [86] Uji SG, Uiterwaal CS, Aldenkamp AP, Carplay JA, Doelman JC, Keizer K, et al. Adjustment of treatment increases quality of life in patients with epilepsy: a randomized controlled pragmatic trial. *Eur J Neurol* 2009;16:1173–7.
- [87] Biton V, Shneker B, Carreno M, Ben-Menachem E, Rocha F, Gama H, et al. Analysis of psychiatric adverse events in three phase iii controlled trials of eslicarbazepine acetate as adjunctive therapy for refractory partial-onset seizures. *Epilepsy Curr* 2015;15:316–7.
- [88] Aldenkamp AP, Vermeulen J, Mulder OG, Overweg J, Van Parys JAP, Beun AM, et al. Gamma-vinyl GABA (vigabatrin) and mood disturbances. *Epilepsia* 1994;35:999–1004.
- [89] Altman HJ, Dworak HA, Halvorsen MB. Safety and pharmacodynamics of USL261, a novel formulation of midazolam optimized for intranasal administration, in subjects with epilepsy. *Epilepsy Curr* 2013;13:164–5.
- [90] Salinsky MC, Oken BS, Binder LM. Assessment of drowsiness in epilepsy patients receiving chronic antiepileptic drug therapy. *Epilepsia* 1996;37:181–7.
- [91] Shah S, Kumar SR, Vivekananda M, Shetty P, Acharya PT, Srinivasa R. Sleep and sexual disturbances in epilepsy. *Ann Indian Acad Neurol* 2010;1:S17.
- [92] Bonanni E, Galli R, Maestri M, Pizzanelli C, Fabbri M, Manca ML, et al. Daytime sleepiness in epilepsy patients receiving topiramate monotherapy. *Epilepsia* 2004;45:333–7.
- [93] Foldvary N, Perry M, Lee J, Dinner D, Morris HH. The effects of lamotrigine on sleep in patients with epilepsy. *Epilepsia* 2001;42:1569–73.
- [94] Peng WF, Ding J, Li X, Mao LY, Wang X. Clinical risk factors for depressive symptoms in patients with epilepsy. *Acta Neurol Scand* 2014;129:343–9.

- [95] Gil-Nagel A, Lopez-Munoz F, Serratosa JM, Moncada I, Garcia-Garcia P, Alamo C. Effect of lamotrigine on sexual function in patients with epilepsy. *Seizure* 2006;15:142–9.
- [96] Luef GJ. Epilepsy and sexuality. *Seizure* 2008;17:127–30.
- [97] de Haas S, Otte A, de Weerd A, van Erp G, Cohen A, van Gerven J. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. *J Clin Sleep Med* 2007;3:473–8.
- [98] Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. *Seizure* 2000;9:375–9.
- [99] Nihira K, Leland H, Lambert N. Adaptive behaviour scales. Austin, TX: American Association on Mental Retardation; 1993.
- [100] Bodfish JW. The habilitative improvement scale. Morganton, NC: Western Carolina Center Research Reports; 1996.
- [101] Wilkin D, Mashiah T, Jolley D. Changes in behavioural characteristics of elderly populations of local authority homes and long-stay hospital wards, 1976–7. *Br Med J* 1978;2:1274–6.
- [102] Baker GA, Jacoby A, Smith DF, Dewey ME, Chadwick DW, et al. Development of a novel scale to assess life fulfillment as part of the further refinement of a quality-of-life model for epilepsy. *Epilepsia* 1994;35:591–6.
- [103] Espie CA, Paul A, Graham M, Sterrick M, Foley J, McGarvey C. The epilepsy outcome scale: the development of a measure for use with carers of people with epilepsy plus intellectual disability. *J Intellect Disabil Res* 1998;42:90–6.
- [104] Matson JL, Boisjoli JA. Cutoff scores for the matson evaluation of social skills for individuals with severe retardation (MESSIER) for adults with intellectual disability. *Behav Modif* 2008;32:109–20.
- [105] Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. *Am J Ment Defic* 1985;89:485–91.
- [106] Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. *J Clin Psychol* 1995;51:768–74.
- [107] Whelan E, Speake B. Challenging behaviour rating scale. University of Manchester; 1985.
- [108] Glogau SJ. Validierung des Fragebogens zur Persönlichkeit bei zerebralen Erkrankungen (FPZ) an einer Stichprobe von Epilepsiepatienten und Gesunden. Bielefeld (Germany): Bielefeld University; 2006.
- [109] Townsend-White C, Pham AN, Vassos MV. Review: a systematic review of quality of life measures for people with intellectual disabilities and challenging behaviours. *J Intellect Disabil Res* 2012;56:270–84.
- [110] Collins dictionary secondary collins dictionary. 2016 Available at: <http://www.collinsdictionary.com/dictionary/english/side-effect> [Accessed 5 May 2016].
- [111] European Commission. Communication from the commission—detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3'). *Off J Eur Union* 2011;1–13 172.
- [112] Basch E. The missing voice of patients in drug-safety reporting. *N Engl J Med* 2010;362:865–9.
- [113] Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. *Support Care Cancer* 2016;1–8.
- [114] Thornicroft G, Tansella M. Mental health outcomes measures. 3rd edn. Royal College of Psychiatrists; 2010.